PR96964

HUNTSVILLE, Ala. and ALAMEDA, Calif., July 13, 2022 /PRNewswire=KYODO JBN/ --

CREATES PREMIER GLOBAL PROVIDER OF CRITICAL STARTING MATERIALS AND ANALYTIC

SERVICES TO ACCELERATE CELL AND GENE THERAPY APPLICATIONS

Discovery Life Sciences (https://c212.net/c/link/?t=0&l=en&o=3590918-1&h=18772439&u=https%3A%2F%2Fwww.dls.com%2F&a=Discovery+Life+Sciences)

(TM) (Discovery), the biospecimen and biomarker specialists (TM), today

announced its acquisition of  AllCells (https://c212.net/c/link/?t=0&l=en&o=3590918-1&h=30026833&u=https%3A%2F%2Fallcells.com%2F&a=AllCells)(R) a leading provider of clinical-grade (GMP-compliant) and Research Use

Only (RUO) primary cell products.  With more than 30 years of collective cell

and gene therapy (CGT) experience, AllCells and Discovery will focus on

providing revolutionary products and services with greater speed and

reliability to satisfy the entire CGT continuum - from basic discovery

through commercialization.  

Logo - https://mma.prnewswire.com/media/1022478/Discovery_LS_Logo.jpg

Logo -  https://mma.prnewswire.com/media/1856962/AllCells_logo.jpg

Founded in 1998 by Jay Tong, M.D., AllCells is a leading global provider in

procuring and customizing primary cell products to support a diversity of CGT

applications.  Combining AllCells' proven industry expertise with Discovery's

biospecimen and biomarker specialization establishes the premier provider for

critical starting materials and analytic services to accelerate CGT

applications.

"We are very excited to welcome the AllCells team to the Discovery family,"

said Discovery CEO Glenn Bilawsky. "Bringing these two great companies together

creates a scalable, end-to-end solution that gives our clients unprecedented

access to reliable human cellular starting materials with integrated multi-omic

analytic services to support cell and gene therapies."

Discovery will combine its existing CGT products and services with AllCells to

create a new business unit called AllCells, a Discovery Life Sciences Company.  

Effective immediately, AllCells CEO and President Danny Zheng will lead the

combined entity.

The combination of Discovery's growing CGT business with AllCells also creates

one of the industry's largest dedicated client donor pools.  The FDA-registered

donor collection facilities and GMP-compliant cleanrooms are located adjacent

to characterization labs.  This proximity strategically enables immediate

processing and cryopreservation for unparalleled quality - providing

customers faster and more cost-effective access to a larger, engaged donor pool

with characterization for client-specific programs.  

Zheng said, "We have built our organization to be an extension of our client's

supply chain.  By offering donor program consulting, high-quality apheresis

collections, customization services, and GMP-compliant starting materials, our

dedicated team will continue to provide a high-touch, client-focused approach

to ensure our clients' needs are met with superior products and services to fit

any timeline and on any scale.  Our strategy parallels and reinforces

Discovery's 'Science at your Service' approach, and our unified offerings will

further accelerate our clients' strategic and vital cell and gene therapy

programs."

"The promise of CGT to impact patient health is unquestionable, but

improvements in manufacturing and reproducibility are needed to expand

addressable patient populations and enhance treatment paradigms," said

Discovery's Chief Technical Officer, CGT Dominic Clarke.  "Our solution

delivers access to the entire continuum from RUO to GMP starting materials,

informed by integrated, comprehensive characterization at scale, to support

these rapidly expanding needs of the industry."  

About Discovery Life Sciences  

Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a

leading provider of highly characterized human cellular starting materials

integrated with expert multi-omic analytical services to advance cell and gene

therapy research, development, and manufacturing.  We offer one of the largest

recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh

and cryopreserved human cellular materials to support cell and gene therapy

programs at any scale from start to finish.

Driven by leading scientific expertise and innovative use of current

technologies, the Discovery team engages and consults with customers to rapidly

overcome obstacles and obtain results to make critical research, development,

and manufacturing decisions at market-leading speed.  We are Science at your

Service (TM)!  For more information, visit

dls.com/cell-and-gene-therapy-products.

About AllCells

For over two decades, AllCells has been a leading provider of high-quality

human primary blood and marrow-based cells.  Through experience and scientific

expertise, AllCells maintains the best-in-class products and services with

optimized protocols that ensure research and clinical-grade products are

delivered on time to pharmaceutical, biotechnology, medical device, healthcare,

and academic institutions around the world.

By consistently delivering high-viability, high-purity subtypes and

guaranteeing an accurate cell count, AllCells has earned a reputation for

high-quality cells with the ability to customize our product to meet even the

most unique requirements.  AllCells – Quality Cells for Quality Science (TM).

SOURCE Discovery Life Sciences

CONTACT:  dls@cglife.com